title: Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.
authors.affiliation: CRCT, UMR1037 Inserm-University, Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France.|Department of Haematology, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
authors.forename: L
authors.initials: L
authors.lastname: Ysebaert
authors.affiliation: CRCT, UMR1037 Inserm-University, Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France.
authors.forename: E
authors.initials: E
authors.lastname: Laprévotte
authors.affiliation: Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Klein
authors.affiliation: CRCT, UMR1037 Inserm-University, Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Quillet-Mary
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000473:pathology*; D015415:Biomarkers; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015415:Biomarkers; D000069283:Rituximab; C543332:obinutuzumab